ArticleFrontiers in neurology
Development and validation of a machine learning model for predicting postherpetic neuralgia risk.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling immune-inflammation-aging network interactions: an interpretable machine learning model predicts the risk of postherpetic neuralgia.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Postherpetic neuralgia (PHN) is a debilitating complication of herpes zoster (HZ), and early identification of high-risk patients is crucial for timely intervention. This study aimed to develop and validate machine learning models to predict the risk of developing PHN following HZ onset. Methods: A retrospective analysis of two prospective cohorts was performed. The training cohort comprised 627 patients from the Affiliated Hospital of Putian University, and an independent external validation cohort included 219 patients from Zhangzhou Affiliated Hospital of Fujian Medical University. Least Absolute Shrinkage and Selection Operator (LASSO) regression and the Boruta algorithm were used for feature selection. Ten ML models were constructed and evaluated based on metrics including the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, F1 score, calibration, and clinical utility. The optimal model was further interpreted using SHapley Additive exPlanations (SHAP). Results: The incidence of PHN was 19.0% (119 of 627) in the training cohort and 22.8% (50 of 219) in the validation cohort. Subsequently, five key risk factors were identified. Among the 10 models, XGBoost exhibited the best comprehensive performance, with an AUC of 0.826 (95%CI: 0.786-0.866) in the training cohort and 0.840 (95%CI: 0.784-0.896) in the validation cohort. SHAP analysis revealed that age was the most important predictor, followed by timing of antiviral therapy, acute pain severity, prodromal phase pain, and diabetes. Conclusion: The XGBoost model based on five clinically accessible factors effectively predicts the risk of PHN. This tool can assist clinicians in early risk stratification and guide personalized management for patients with HZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.